Graig Suvannavejh
Stock Analyst at Mizuho
(4.40)
# 361
Out of 5,131 analysts
173
Total ratings
56.92%
Success rate
16.51%
Average return
Main Sectors:
Stocks Rated by Graig Suvannavejh
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PVLA Palvella Therapeutics | Initiates: Outperform | $205 | $100.49 | +104.00% | 1 | Jan 7, 2026 | |
| ERAS Erasca | Maintains: Outperform | $4 → $5 | $6.23 | -19.74% | 1 | Dec 9, 2025 | |
| TERN Terns Pharmaceuticals | Maintains: Outperform | $33 → $54 | $34.11 | +58.31% | 9 | Dec 9, 2025 | |
| BLTE Belite Bio | Upgrades: Outperform | $105 → $194 | $155.36 | +24.87% | 2 | Dec 2, 2025 | |
| INSM Insmed | Maintains: Outperform | $196 → $256 | $167.72 | +52.64% | 12 | Dec 1, 2025 | |
| HRMY Harmony Biosciences Holdings | Maintains: Outperform | $39 → $46 | $38.27 | +20.20% | 21 | Dec 1, 2025 | |
| TARS Tarsus Pharmaceuticals | Initiates: Outperform | $100 | $75.53 | +32.40% | 1 | Nov 20, 2025 | |
| IMTX Immatics | Maintains: Outperform | $19 → $23 | $9.16 | +151.09% | 4 | Nov 19, 2025 | |
| HALO Halozyme Therapeutics | Maintains: Neutral | $54 → $56 | $72.42 | -22.67% | 7 | Nov 18, 2025 | |
| IDYA IDEAYA Biosciences | Maintains: Outperform | $44 → $46 | $36.84 | +24.86% | 3 | Nov 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $200 → $202 | $176.82 | +14.24% | 22 | Nov 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $24 → $19 | $23.20 | -18.10% | 11 | Nov 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $2 → $4 | $2.02 | +98.02% | 9 | Sep 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $30 | $0.64 | +4,587.50% | 1 | Sep 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $2.5 → $3.5 | $1.85 | +89.19% | 5 | Jul 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $4 → $5 | $2.22 | +125.23% | 2 | Jul 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $8 → $10 | $4.22 | +136.97% | 2 | Jun 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $12 → $11 | $6.75 | +62.96% | 3 | May 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $30 → $26 | $15.94 | +63.11% | 5 | May 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $7 → $8 | $12.39 | -35.43% | 7 | May 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $38 → $33 | $32.65 | +1.09% | 8 | Apr 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $7 → $7.6 | $1.50 | +406.67% | 1 | Nov 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $74 | $7.99 | +826.16% | 1 | Sep 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $50 → $5 | $6.75 | -25.93% | 3 | Sep 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $17 → $1 | $3.59 | -72.14% | 5 | Jun 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $31 → $35 | $104.89 | -66.63% | 5 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $9 → $8 | $28.06 | -71.49% | 6 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $71 → $57 | $64.64 | -11.82% | 2 | May 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sell | $8 → $5 | $27.72 | -81.96% | 4 | Apr 19, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $34 | $9.85 | +245.18% | 1 | Jun 1, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $28 | $9.12 | +207.02% | 1 | Apr 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $31 | $24.13 | +28.47% | 1 | Apr 19, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sell | $380 | $14.15 | +2,585.51% | 1 | Mar 2, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $4.75 | $1.85 | +156.76% | 1 | Nov 24, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $36 | $26.78 | +34.43% | 2 | Nov 9, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | n/a | $33.11 | - | 1 | Oct 21, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $37 | $2.20 | +1,581.82% | 1 | Oct 20, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | $128 | $163.68 | -21.80% | 1 | Sep 14, 2020 |
Palvella Therapeutics
Jan 7, 2026
Initiates: Outperform
Price Target: $205
Current: $100.49
Upside: +104.00%
Erasca
Dec 9, 2025
Maintains: Outperform
Price Target: $4 → $5
Current: $6.23
Upside: -19.74%
Terns Pharmaceuticals
Dec 9, 2025
Maintains: Outperform
Price Target: $33 → $54
Current: $34.11
Upside: +58.31%
Belite Bio
Dec 2, 2025
Upgrades: Outperform
Price Target: $105 → $194
Current: $155.36
Upside: +24.87%
Insmed
Dec 1, 2025
Maintains: Outperform
Price Target: $196 → $256
Current: $167.72
Upside: +52.64%
Harmony Biosciences Holdings
Dec 1, 2025
Maintains: Outperform
Price Target: $39 → $46
Current: $38.27
Upside: +20.20%
Tarsus Pharmaceuticals
Nov 20, 2025
Initiates: Outperform
Price Target: $100
Current: $75.53
Upside: +32.40%
Immatics
Nov 19, 2025
Maintains: Outperform
Price Target: $19 → $23
Current: $9.16
Upside: +151.09%
Halozyme Therapeutics
Nov 18, 2025
Maintains: Neutral
Price Target: $54 → $56
Current: $72.42
Upside: -22.67%
IDEAYA Biosciences
Nov 11, 2025
Maintains: Outperform
Price Target: $44 → $46
Current: $36.84
Upside: +24.86%
Nov 6, 2025
Maintains: Outperform
Price Target: $200 → $202
Current: $176.82
Upside: +14.24%
Nov 3, 2025
Maintains: Neutral
Price Target: $24 → $19
Current: $23.20
Upside: -18.10%
Sep 12, 2025
Maintains: Neutral
Price Target: $2 → $4
Current: $2.02
Upside: +98.02%
Sep 8, 2025
Initiates: Outperform
Price Target: $30
Current: $0.64
Upside: +4,587.50%
Jul 28, 2025
Upgrades: Outperform
Price Target: $2.5 → $3.5
Current: $1.85
Upside: +89.19%
Jul 16, 2025
Maintains: Outperform
Price Target: $4 → $5
Current: $2.22
Upside: +125.23%
Jun 18, 2025
Maintains: Outperform
Price Target: $8 → $10
Current: $4.22
Upside: +136.97%
May 20, 2025
Maintains: Outperform
Price Target: $12 → $11
Current: $6.75
Upside: +62.96%
May 16, 2025
Maintains: Outperform
Price Target: $30 → $26
Current: $15.94
Upside: +63.11%
May 14, 2025
Maintains: Outperform
Price Target: $7 → $8
Current: $12.39
Upside: -35.43%
Apr 7, 2025
Maintains: Neutral
Price Target: $38 → $33
Current: $32.65
Upside: +1.09%
Nov 18, 2024
Upgrades: Buy
Price Target: $7 → $7.6
Current: $1.50
Upside: +406.67%
Sep 20, 2024
Reiterates: Outperform
Price Target: $74
Current: $7.99
Upside: +826.16%
Sep 19, 2024
Downgrades: Neutral
Price Target: $50 → $5
Current: $6.75
Upside: -25.93%
Jun 5, 2023
Downgrades: Neutral
Price Target: $17 → $1
Current: $3.59
Upside: -72.14%
Nov 10, 2022
Maintains: Buy
Price Target: $31 → $35
Current: $104.89
Upside: -66.63%
Nov 10, 2022
Maintains: Neutral
Price Target: $9 → $8
Current: $28.06
Upside: -71.49%
May 24, 2022
Maintains: Buy
Price Target: $71 → $57
Current: $64.64
Upside: -11.82%
Apr 19, 2022
Maintains: Sell
Price Target: $8 → $5
Current: $27.72
Upside: -81.96%
Jun 1, 2021
Initiates: Buy
Price Target: $34
Current: $9.85
Upside: +245.18%
Apr 20, 2021
Initiates: Neutral
Price Target: $28
Current: $9.12
Upside: +207.02%
Apr 19, 2021
Initiates: Neutral
Price Target: $31
Current: $24.13
Upside: +28.47%
Mar 2, 2021
Initiates: Sell
Price Target: $380
Current: $14.15
Upside: +2,585.51%
Nov 24, 2020
Initiates: Neutral
Price Target: $4.75
Current: $1.85
Upside: +156.76%
Nov 9, 2020
Upgrades: Buy
Price Target: $36
Current: $26.78
Upside: +34.43%
Oct 21, 2020
Downgrades: Sell
Price Target: n/a
Current: $33.11
Upside: -
Oct 20, 2020
Initiates: Neutral
Price Target: $37
Current: $2.20
Upside: +1,581.82%
Sep 14, 2020
Downgrades: Sell
Price Target: $128
Current: $163.68
Upside: -21.80%